Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

AIMS: The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to investigate t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ESC Heart Fail
Päätekijät: Pellicori, Pierpaolo, Ofstad, Anne Pernille, Fitchett, David, Zeller, Cordula, Wanner, Christoph, George, Jyothis, Zinman, Bernard, Brueckmann, Martina, Lindenfeld, JoAnn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Short Communications
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754994/
https://ncbi.nlm.nih.gov/pubmed/32915523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12891
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia